The number of countries that have recognized the Livalo’s safety of diabetes in the treatment of dyslipidemia is expanding from Europe to East Asia and the Middle East.
JW Pharmaceutical announced on Dec. 22 that the number of countries that recognize the safety of diabetes in Livalo (component name: pitavastatin) has increased from 21 countries to 31 countries.
The additional 10 countries identified include Singapore, Malaysia, Lebanon, Saudi Arabia, Bahrain, Jordan, Kuwait, Oman, Qatar and the United Arab Emirates.
Starting with the Britain in March 2016, a total of 21 countries including Portugal, Greece, Germany, France, Ireland and Austria approved it until August last year. Currently, a total of 31 countries can insert the phrase "no signs of diabetes risk" in the drug manual (SmPC). It is the only Statin family.
The countries officially acknowledged the safety of Livalo based on the results of a meta-analysis study that comprehensively compared the results of J-PREDICT study and 15 studies conducted with pitavastatin drugs that reduced the risk of diabetes by 18% in preparation for placebo.
In the large-scale and long-term clinical trial (REAL-CAD study, 2018), which was the first of its kind among statin-family drugs, high-capacity statins are effective in reducing the risk of major cardiovascular diseases compared to low doses, and new diabetes mobility rates are no different from low doses.
The TOHO-LIP (2020 published) study on dyslipidemia patients with more than one risk factor for arteriosclerosis disease proved the effectiveness of pitavastatin in preventing major cardiovascular diseases.
Recently, a Taiwanese clinical trial comparing the rate of new diabetes between statin drugs for non-diabetic patients confirmed that the incidence of diabetes in pitavastatin is significantly lower compared to other statin drugs.
A JW Pharmaceutical official said, "A variety of recent academic data, including clinical trials, has proved once again that pitavastatin is the only Statin drug that has a low risk of diabetes."
